Vice President, Uro-Oncology Business Unit
David is responsible for the Uro-Oncology Business Unit.
David has more than 25 years of pharmaceutical industry experience working in the U.S. global and Asian markets. He joined Ferring in 2019 as the Commercialization Leader of the Microbiome Franchise. Prior to Ferring, he was as a franchise leader at Melinta Therapeutics, previously The Medicine Company. David began his career at Schering Pharmaceuticals, later, Merck & Company, gaining diverse experience in finance, sales operations, sales, and marketing.
David Bell holds an MBA in finance and bachelor of science in finance from Seton Hall University in New Jersey.